Schwartz C, Khorsandi N, Blanco A, Mukhtar R, Chen Y, Krings G
Breast Cancer Res Treat. 2023; 204(1):171-179.
PMID: 38091153
PMC: 10806021.
DOI: 10.1007/s10549-023-07176-8.
Smid M, Schmidt M, Prager-van der Smissen W, Ruigrok-Ritstier K, Schreurs M, Cornelissen S
Breast Cancer Res. 2023; 25(1):53.
PMID: 37161532
PMC: 10169359.
DOI: 10.1186/s13058-023-01653-0.
van den Ende N, Smid M, Timmermans A, van Brakel J, Hansum T, Foekens R
Sci Rep. 2022; 12(1):12974.
PMID: 35902644
PMC: 9334272.
DOI: 10.1038/s41598-022-16898-6.
Iyevleva A, Aleksakhina S, Sokolenko A, Baskina S, Venina A, Anisimova E
Breast Cancer Res Treat. 2022; 192(2):283-291.
PMID: 35020107
DOI: 10.1007/s10549-022-06517-3.
Southey M, Dowty J, Riaz M, Steen J, Renault A, Tucker K
NPJ Breast Cancer. 2021; 7(1):153.
PMID: 34887416
PMC: 8660783.
DOI: 10.1038/s41523-021-00360-3.
Increased gene expression variability in BRCA1-associated and basal-like breast tumours.
Wiggins G, Black M, Dunbier A, Morley-Bunker A, Pearson J, Walker L
Breast Cancer Res Treat. 2021; 189(2):363-375.
PMID: 34287743
PMC: 8357684.
DOI: 10.1007/s10549-021-06328-y.
Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study.
Li N, Lim B, Thompson E, McInerny S, Zethoven M, Cheasley D
NPJ Breast Cancer. 2021; 7(1):76.
PMID: 34117267
PMC: 8196173.
DOI: 10.1038/s41523-021-00279-9.
Population-Based Estimates of the Age-Specific Cumulative Risk of Breast Cancer for Pathogenic Variants in : Findings from the Australian Breast Cancer Family Registry.
Nguyen-Dumont T, Dowty J, Steen J, Renault A, Hammet F, Mahmoodi M
Cancers (Basel). 2021; 13(6).
PMID: 33803639
PMC: 8003064.
DOI: 10.3390/cancers13061378.
Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.
Stolarova L, Kleiblova P, Janatova M, Soukupova J, Zemankova P, Macurek L
Cells. 2020; 9(12).
PMID: 33322746
PMC: 7763663.
DOI: 10.3390/cells9122675.
TEffectR: an R package for studying the potential effects of transposable elements on gene expression with linear regression model.
Karakulah G, Arslan N, Yandim C, Suner A
PeerJ. 2019; 7:e8192.
PMID: 31824778
PMC: 6899341.
DOI: 10.7717/peerj.8192.
Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
Wang Y, Ung M, Cantor S, Cheng C
Sci Rep. 2017; 7(1):15742.
PMID: 29146938
PMC: 5691048.
DOI: 10.1038/s41598-017-16138-2.
Transcriptional signature of lymphoblastoid cell lines of , and non- high risk breast cancer families.
Pouliot M, Kothari C, Joly-Beauparlant C, Labrie Y, Ouellette G, Simard J
Oncotarget. 2017; 8(45):78691-78712.
PMID: 29108258
PMC: 5667991.
DOI: 10.18632/oncotarget.20219.
Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline :c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.
Thibodeau M, Reisle C, Zhao E, Martin L, Alwelaie Y, Mungall K
Cold Spring Harb Mol Case Stud. 2017; 3(5).
PMID: 28514723
PMC: 5593158.
DOI: 10.1101/mcs.a001628.
Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
Muranen T, Blomqvist C, Dork T, Jakubowska A, Heikkila P, Fagerholm R
Breast Cancer Res. 2016; 18(1):98.
PMID: 27716369
PMC: 5048645.
DOI: 10.1186/s13058-016-0758-5.
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
Schmidt M, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank M
J Clin Oncol. 2016; 34(23):2750-60.
PMID: 27269948
PMC: 5019754.
DOI: 10.1200/JCO.2016.66.5844.
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
Massink M, Kooi I, Martens J, Waisfisz Q, Meijers-Heijboer H
BMC Cancer. 2015; 15:877.
PMID: 26553136
PMC: 4640207.
DOI: 10.1186/s12885-015-1880-y.
Genotype/Phenotype correlations in patients with hereditary breast cancer.
Wittersheim M, Buttner R, Markiefka B
Breast Care (Basel). 2015; 10(1):22-6.
PMID: 25960721
PMC: 4395815.
DOI: 10.1159/000380900.
Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
Kriege M, Jager A, Hollestelle A, Berns E, Blom J, Meijer-Van Gelder M
J Cancer Res Clin Oncol. 2015; 141(10):1879-87.
PMID: 25958056
PMC: 4543421.
DOI: 10.1007/s00432-015-1981-7.
Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
Massink M, Kooi I, van Mil S, Jordanova E, Ameziane N, Dorsman J
Mol Oncol. 2015; 9(4):877-88.
PMID: 25616998
PMC: 5528776.
DOI: 10.1016/j.molonc.2014.12.012.
Emerging Concepts in Breast Cancer Risk Prediction.
Gierach G, Yang X, Figueroa J, Sherman M
Curr Obstet Gynecol Rep. 2014; 2(1):43-52.
PMID: 25506515
PMC: 4262133.
DOI: 10.1007/s13669-012-0034-3.